(Q34551578)

3 August 2017

1 reference

title

The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics (English)

1 reference

3 August 2017

1 reference

1 reference

E. K. Rowinsky

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687171

29 October 2022

R. C. Donehower

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1687171

29 October 2022

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1687171

29 October 2022

publication date

1 October 1991

1 reference

full work available at URL

3 August 2017

https://api.elsevier.com/content/article/PII:0163725891900862?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

https://api.elsevier.com/content/article/PII:0163725891900862?httpAccept=text/plain

29 October 2022

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacology & Therapeutics

29 October 2022

published in

1 reference

3 August 2017

52

1 reference

3 August 2017

35-84

1 reference

3 August 2017

1

1 reference

Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer

3 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Caerulein treatment for paralytic ileus

29 October 2022

2

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine, adriamycin and high dose steroids in myeloma complicated by renal failure

29 October 2022

3

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II trial of spirogermanium and vindesine in malignant glioma.

29 October 2022

5

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

VAD-based regimens as primary treatment for multiple myeloma

29 October 2022

7

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy for advanced non-Hodgkin's lymphomas other than diffuse histiocytic or undifferentiated histologies

29 October 2022

10

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Inappropriate antidiuretic hormone secretion after high dose vinblastine.

29 October 2022

11

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with the CHOP regimen

29 October 2022

13

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Better survival after combined modality care for adults with Wilms' tumor. A report from the National Wilms' Tumor Study

29 October 2022

14

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Childhood acute lymphocytic leukemia. Study VIII

29 October 2022

15

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, vinblastine, and bleomycin combination in the treatment of resistant high-risk gestational trophoblastic tumors.

29 October 2022

16

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study

29 October 2022

18

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of non-small cell lung cancer: a reappraisal and a look to the future

29 October 2022

19

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effective treatment of advanced multiple myeloma refractory to alkylating agents.

29 October 2022

22

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase-II trial with vindesine for regression induction in patients with leukemias and hematosarcomas

29 October 2022

25

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The cell biology of multiple drug resistance

29 October 2022

28

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The pharmacokinetics of [3H]-vincristine in man

29 October 2022

32

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Microtubular crystals in mammalian cells

29 October 2022

33

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Long-term remission in diffuse histiocytic lymphoma treated with combination sequential chemotherapy

29 October 2022

34

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Sequential cisplatin/VM-26 and vincristine/cyclophosphamide/doxorubicin in metastatic neuroblastoma: an effective alternating non-cross-resistant regimen?

29 October 2022

35

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of children with refractory acute lymphocytic leukemia with vincristine and diltiazem.

29 October 2022

37

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Tubulin aggregation and disaggregation: mediation by two distinct vinblastine-binding sites

29 October 2022

39

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Immunofluorescence study of the action of navelbine, vincristine and vinblastine on mitotic and axonal microtubules

29 October 2022

41

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Transient cortical blindness secondary to vincristine therapy in childhood malignancies

29 October 2022

42

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of alkylating resistant multiple myeloma with vincristine, BCNU, doxorubicin and prednisone (VBAP).

29 October 2022

46

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized multicentric study comparing alternating combination chemotherapy (VCMP/VBAP) and melphalan-prednisone in multiple myeloma

29 October 2022

47

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Continuous infusion vindesine in solid tumors

29 October 2022

51

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine in the treatment of lymphomas and leukemias

29 October 2022

53

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Decreased phenytoin level during antineoplastic therapy: a case report

29 October 2022

54

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

29 October 2022

55

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

29 October 2022

56

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas

29 October 2022

57

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of a new anticancer drug, navelbine, in patients. Comparative study of radioimmunologic and radioactive determination methods

29 October 2022

58

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

VAB-6: an effective chemotherapy regimen for patients with germ-cell tumors

29 October 2022

60

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors

29 October 2022

61

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Severe ileus from cisplatin and vinblastine infusion in neuroblastoma

29 October 2022

62

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

COPBLAM III: infusional combination chemotherapy for diffuse large-cell lymphoma

29 October 2022

63

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies

29 October 2022

64

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Verapamil reversal of vincristine resistance and cross-resistance patterns of vincristine-resistant Chinese hamster ovary cells

29 October 2022

66

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase I trial of taxol given by a 6-hour intravenous infusion

29 October 2022

68

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Definition of three classes of binding sites in isolated microtubule crystals

29 October 2022

69

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine and microtubules. II. Characterization of two protein subunits from the isolated crystals

29 October 2022

70

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I trial of intravenous vinzolidine (LY 104208) given on a biweekly dosing schedule

29 October 2022

73

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The effects of colcemid on hematopoiesis in the mouse

29 October 2022

74

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II

29 October 2022

75

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division

29 October 2022

76

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly

29 October 2022

77

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A mechanism of cellular resistance to drugs that interfere with microtubule assembly

29 October 2022

78

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Successful chemotherapy for recurrent malignant oligodendroglioma.

29 October 2022

79

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy with vincristine (NSC-67574), procarbazine (NSC-77213), prednisone (NSC-10023) with or without nitrogen mustard (NSC-762)(MOPP vs OPP) in children with recurrent brain tumors.

29 October 2022

82

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol effect on tubulin polymerization and associated guanosine 5'-triphosphate hydrolysis

29 October 2022

86

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Orthostatic hypotension during vincristine therapy

29 October 2022

87

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparison of M-2 protocol with COP in patients with nodular lymphoma

29 October 2022

89

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

29 October 2022

90

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combined hormonal therapy with high-dose diethylstilbestrol diphosphate (DES-DP) intravenous infusion plus vindesine (VND) for the treatment of advanced prostatic carcinoma: a controlled study

29 October 2022

93

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Germ cell tumors (II). VAB II in metastatic testicular cancer

29 October 2022

94

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

An altered pattern of cross-resistance in multidrug-resistant human cells results from spontaneous mutations in the mdr1 (P-glycoprotein) gene

29 October 2022

96

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of childhood medulloblastoma

29 October 2022

97

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

LNH-84 regimen: a multicenter study of intensive chemotherapy in 737 patients with aggressive malignant lymphoma

29 October 2022

100

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Temperature-dependent reversible assembly of taxol-treated microtubules

29 October 2022

103

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease

29 October 2022

107

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Initial clinical studies with vincristine

29 October 2022

108

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized trial of the immunosuppressive efficacy of vincristine in cardiac transplantation

29 October 2022

110

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Experimental antitumor activity of Navelbine

29 October 2022

114

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Evidence that microtubule depolymerization early in the cell cycle is sufficient to initiate DNA synthesis

29 October 2022

115

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Microtubules and lymphocyte responses: Effect of colchicine and taxol on mitogen-induced human lymphocyte activation and proliferation

29 October 2022

118

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy.

29 October 2022

120

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

m-BACOD treatment for intermediate- and high-grade malignant lymphomas: a Southwest Oncology Group phase II trial

29 October 2022

121

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Failure of the perioperative PCV neoadjuvant polychemotherapy in resectable bronchogenic non-small cell carcinoma. Results from a randomized phase II trial

29 October 2022

122

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of mitomycin C and vinblastine in women with advanced breast cancer refractory to standard cytotoxic therapy

29 October 2022

124

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Can severe vincristine neurotoxicity be prevented?

29 October 2022

127

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture

29 October 2022

128

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

29 October 2022

130

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Advanced diffuse histiocytic lymphoma, a potentially curable disease

29 October 2022

131

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I study of 21 days continuous infusion with vindesine

29 October 2022

133

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer

29 October 2022

134

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine in advanced breast cancer, lymphoma and melanoma. A Colorado Clinical Oncology Group study

29 October 2022

135

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cyclophosphamide, vinblastine, procarbazine and prednisone with CCNU and vinblastine maintenance for advanced Hodgkin's disease

29 October 2022

137

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer

29 October 2022

138

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Shared actions of endotoxin and taxol on TNF receptors and TNF release

29 October 2022

139

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on axonal fibrillar organelles in vitro

29 October 2022

142

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinca alkaloid skin toxicity: antidote and drug disposition studies in the mouse

29 October 2022

143

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy in recurrent medulloblastoma

29 October 2022

146

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

29 October 2022

Microtubules

148

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Undifferentiated epithelial-rich invasive malignant thymoma: complete response to cisplatin, vinblastine, and bleomycin therapy

29 October 2022

149

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Acute bronchospasm after a vinca alkaloid in patients previously treated with mitomycin

29 October 2022

150

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cholesterol embolization after treatment with tissue plasminogen activator

29 October 2022

151

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I anti-cancer agents: vindesine (desacetyl vinblastine amide sulfate).

29 October 2022

152

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Surface modulation in cell recognition and cell growth

29 October 2022

153

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cis-Diamminedichloroplatinum, Vinblastine, and Bleomycin Combination Chemotherapy in Disseminated Testicular Cancer

29 October 2022

154

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of disseminated testicular cancer a random prospective study

29 October 2022

155

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The role of maintenance therapy in disseminated testicular cancer

29 October 2022

156

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase II study of taxol in patients with malignant melanoma

29 October 2022

160

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: A randomized study

29 October 2022

162

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma

29 October 2022

163

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Intralesional vinblastine for oral Kaposi sarcoma in HIV infection

29 October 2022

164

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Oral Kaposi's sarcoma in acquired immunodeficiency syndrome. Review of management and report of the efficacy of intralesional vinblastine

29 October 2022

165

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine: a phase II study in childhood malignancies-a report for cancer and leukemia group B.

29 October 2022

167

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The treatment of medulloblastoma. Results of a prospective randomized trial of radiation therapy with and without CCNU, vincristine, and prednisone

29 October 2022

168

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma

29 October 2022

170

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparison of antitumor activity of standard and investigational drugs at equivalent granulocyte-macrophage colony-forming cell inhibitory concentrations in the adhesive tumor cell culture system: an in vitro method of screening new drugs

29 October 2022

172

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vincristine in cancer patients treated with nifedipine

29 October 2022

174

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Biochemical effects of Navelbine on tubulin and associated proteins

29 October 2022

175

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases

29 October 2022

176

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Differential activity of vincristine and vinblastine against cultured cells

29 October 2022

177

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy

29 October 2022

179

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

29 October 2022

181

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Five-day continuous-infusion vinblastine in the treatment of breast cancer

29 October 2022

183

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Percutaneous hepatic arterial infusion of cisplatin-vinblastine for refractory breast carcinoma metastatic to the liver

29 October 2022

184

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin in Combination with Continuous Infusion Vinblastine for Refractory Breast Cancer

29 October 2022

185

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Efficacy of vincristine and cyclophosphamide in the therapy of recurrent medulloblastoma.

29 October 2022

186

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cytologic evidence that taxol, an antineoplastic agent from Taxus brevifolia, acts as a mitotic spindle poison

29 October 2022

187

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Stimulation of Tubulin-Dependent ATPase Activity in Microtubule Proteins from Porcine Brain by Taxol

29 October 2022

188

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Intrathecal vincristine. Report of a fatal case despite CNS washout

29 October 2022

190

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide.

29 October 2022

192

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of advanced breast cancer with mitomycin C combined with vinblastine or vindesine

29 October 2022

195

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers

29 October 2022

196

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of divided-dose vinblastine in advanced breast cancer patients

29 October 2022

197

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pulmonary Kaposi's sarcoma: clinical findings and results of therapy

29 October 2022

199

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of Advanced Kaposiʼs Sarcoma Using a Combination of Bleomycin and Vincristine

29 October 2022

200

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine and inappropriate ADH secretion

29 October 2022

201

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

High-dose combination chemotherapy for acute nonlymphoblastic leukemia in adults.

29 October 2022

203

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of invasive thymoma. A retrospective study of 22 cases

29 October 2022

204

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Use of vinblastine in the terminal phase of chronic myelocytic leukemia

29 October 2022

206

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine-induced bladder atony

29 October 2022

208

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine a review of phase-II trials

29 October 2022

212

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

29 October 2022

213

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study

29 October 2022

214

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Platinum-based combination chemotherapy in advanced non-small cell lung cancer: a randomized phase II trial of the Cancer and Leukemia Group B.

29 October 2022

215

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Preparation of vinblastine-4-acetyl-t and its distribution in the blood of rats

29 October 2022

218

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Brain uptake and anticancer activities of vincristine and vinblastine are restricted by their low cerebrovascular permeability and binding to plasma constituents in rat.

29 October 2022

219

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro

29 October 2022

222

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Folinic Acid Rescue for Vincristine Toxicity

29 October 2022

223

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol resistant mutants of Chinese hamster ovary cells: genetic biochemical, and cross-resistance studies.

29 October 2022

224

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The hemolytic-uremic syndrome: recovery after treatment with vincristine

29 October 2022

227

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine pharmacokinetics measured by a sensitive enzyme-linked immunosorbent assay

29 October 2022

228

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Intensive chemotherapy in children with acute lymphoblastic leukemia (L-2 protocol)

29 October 2022

229

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Curative combination chemotherapy for patients with advanced poorly differentiated carcinoma of unknown primary site

29 October 2022

230

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of advanced non-small-cell lung cancer: a randomized trial of three cis-platin-based chemotherapy regimens

29 October 2022

231

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Randomised study of MOPP (mustine, Oncovin, procarbazine, prednisone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease. British National Lymphoma Investigation

29 October 2022

235

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Toxicity and pharmacology of bolus vindesine injection and prolonged vindesine infusion

29 October 2022

236

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine in the treatment of metastatic breast cancer

29 October 2022

237

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold

29 October 2022

238

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Raynaud's phenomenon in patients treated with cisplatin, vinblastine, and bleomycin for germ cell cancer: measurement of vasoconstrictor response to cold

29 October 2022

239

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Long-term neurotoxicity in patients treated with cisplatin, vinblastine, and bleomycin for metastatic germ cell cancer

29 October 2022

240

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Nifedipine and oncologic Raynaud phenomenon

29 October 2022

241

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Symptom relief with moderate dose chemotherapy (mitomycin-C, vinblastine and cisplatin) in advanced non-small cell lung cancer

29 October 2022

242

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study.

29 October 2022

243

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Lactulose in vincristine-induced constipation

29 October 2022

244

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Myocardial ischaemia, radiotherapy, and vinblastine

29 October 2022

245

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

One-day VATH (vinblastine, Adriamycin, thiotepa, and Halotestin) therapy for advanced breast cancer refractory to chemotherapy

29 October 2022

246

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The binding of vinblastine by platelets in the rat

29 October 2022

247

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Reduction of vincristine toxicity by Cronassial

29 October 2022

249

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Results of induction therapy with vincristine and prednisone alone in adult acute lymphoblastic leukemia: report of 43 patients and review of the literature

29 October 2022

253

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparative effects of vincristine and vindesine on cell cycle kinetics in vitro

29 October 2022

254

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine treatment of acute lymphoblastic leukemia induces transient autonomic cardioneuropathy

29 October 2022

255

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

29 October 2022

259

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, ifosfamide and vindesine in the chemotherapy of non-small-cell lung cancer: a combination phase II study

29 October 2022

261

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: mechanisms of action and resistance.

29 October 2022

264

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effects of taxol and nocodazole on insulin secretion from isolated rat islets of Langerhans

29 October 2022

266

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest

29 October 2022

267

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Current status of the therapy of advanced renal carcinoma

29 October 2022

268

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Maytansine inhibits nucleotide binding at the exchangeable site of tubulin.

29 October 2022

269

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Reversible encephalopathy and seizures as a result of conventional vincristine administration

29 October 2022

270

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol inhibits N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced human neutrophil polarization and H2O2 production while decreasing [3H]FMLP binding

29 October 2022

271

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine-induced fever in children with leukemia and lymphoma

29 October 2022

274

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pulmonary edema associated with intravenous vinblastine

29 October 2022

275

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer

29 October 2022

276

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Biliary excretion of vincristine

29 October 2022

279

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vincristine in the cerebrospinal fluid of subhuman primates

29 October 2022

280

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vincristine in the cerebrospinal fluid of humans

29 October 2022

281

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vincristine infusion

29 October 2022

282

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of vincristine-induced ileus with sincalide, a cholecystokinin analog

29 October 2022

283

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Synergistic antitumor activity of vincristine and VP-16-213

29 October 2022

284

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion

29 October 2022

285

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Hepatic intra-arterial infusion of vincristine.

29 October 2022

286

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vindesine bolus and infusion

29 October 2022

287

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Single agent vincristine by infusion in refractory multiple myeloma

29 October 2022

288

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of vincristine infusion in refractory small cell carcinoma of the lung

29 October 2022

289

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine infusion in refractory gynecologic malignancies

29 October 2022

290

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Clinical trial of folinic acid to reduce vincristine neurotoxicity

29 October 2022

291

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Clinical trial of pyridoxine to reduce vincristine neurotoxicity

29 October 2022

292

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine infusion in non-Hodgkin's lymphomas: lack of total cross-resistance with vincristine

29 October 2022

293

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Amelioration of vincristine neurotoxicity by glutamic acid

29 October 2022

294

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Infusion of etoposide and vincristine in non-Hodgkin's lymphoma

29 October 2022

295

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine infusion with CHOP-CCNU in diffuse large-cell lymphoma

29 October 2022

296

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination high-dose etoposide and vincristine infusion

29 October 2022

297

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Altered phenytoin clearance during intensive chemotherapy for acute lymphoblastic leukemia

29 October 2022

299

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetic and preliminary metabolic fate of navelbine in humans as determined by high performance liquid chromatography

29 October 2022

301

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Lymphomatoid granulomatosis. A case for aggressive therapy

29 October 2022

302

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group

29 October 2022

303

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer

29 October 2022

304

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia

29 October 2022

306

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparison of adriamycin-containing chemotherapy (MOP-BAP) with MOPP-Bleomycin in the management of advanced Hodgkin's disease. A Southwest Oncology Group Study

29 October 2022

307

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

New agents in non-small cell lung cancer

29 October 2022

308

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center

29 October 2022

309

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants

29 October 2022

310

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Desacetyl vinblastine amide sulfate induced ineffective erythropoiesis

29 October 2022

311

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results

29 October 2022

312

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia

29 October 2022

315

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Are vinca alkaloids associated with myocardial infarction?

29 October 2022

316

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine-vinblastine regimen

29 October 2022

317

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neurotoxicity of antineoplastic drugs

29 October 2022

318

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effects of infused histamine: analysis of the effects of H-1 and H-2 histamine receptor antagonists on cardiovascular and pulmonary responses

29 October 2022

319

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Overdosage with vincristine

29 October 2022

320

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Reduced effect of taxol on plasma protein secretion by developing rat liver

29 October 2022

321

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, doxorubicin, cyclophosphamide, and vindesine combination chemotherapy for non-small cell lung cancer

29 October 2022

323

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Preoperative therapy for esophageal cancer: a randomized comparison of chemotherapy versus radiation therapy

29 October 2022

324

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized study of two different schedules of methyl CCNU, 5-FU and vincristine for metastatic colorectal carcinoma

29 October 2022

325

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Histologic disappearance of locally advanced vaginal cancer after combination chemotherapy

29 October 2022

326

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy with cisplatin, etoposide, and vindesine in non-small cell lung carcinoma: a clinical trial of the EORTC lung cancer working party

29 October 2022

328

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

MOPP/ABV hybrid program: combination chemotherapy based on early introduction of seven effective drugs for advanced Hodgkin's disease

29 October 2022

329

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma

29 October 2022

330

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Updated clinical experience with MACOP-B

29 October 2022

331

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Mitomycin C and vinblastine chemotherapy for advanced breast cancer

29 October 2022

332

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Clinical pharmacology of vinzolidine

29 October 2022

333

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pre-irradiation chemotherapy for infants and children with medulloblastoma: a preliminary report.

29 October 2022

334

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The natural history and treatment of epidemic Kaposi's sarcoma

29 October 2022

335

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Dyspnea following vinblastine or vindesine administration in patients receiving mitomycin plus vinca alkaloid combination therapy

29 October 2022

337

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment

29 October 2022

339

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Trial of vindesine plus mitomycin in stage-3 non-small cell lung cancer. An active regimen for outpatient treatment

29 October 2022

340

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I trial of taxol given as a 3-hour infusion every 21 days

29 October 2022

341

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Dose-intensive use of cyclophosphamide in ablation of neuroblastoma

29 October 2022

344

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

An enzyme-linked immunosorbent assay for the antineoplastic agent vincristine

29 October 2022

345

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Discordance in the development of peripheral and autonomic neuropathy during vincristine therapy

29 October 2022

346

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit

29 October 2022

347

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Drug-Induced Neurological Disorders

29 October 2022

349

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effect of vincristine sulphate on the intracranial gliomata of childhood.

29 October 2022

350

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination Chemotherapy of Advanced Diffuse Histiocytic Lymphoma with the Six-Drug COP-BLAM Regimen

29 October 2022

352

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Myocardial infarction following vinblastine treatment

29 October 2022

355

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Results of the treatment of children with recurrent gliomas with lomustine and vincristine.

29 October 2022

356

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Results of treatment of children with recurrent medulloblastoma/primitive neuroectodermal tumors with lomustine, cisplatin, and vincristine

29 October 2022

357

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine neurotoxicity. Pathophysiology and management.

29 October 2022

358

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I study of taxol using a 5-day intermittent schedule

29 October 2022

359

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase II trial of taxol in metastatic melanoma

29 October 2022

360

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Varying prednisone dosage in remission induction of previously untreated childhood leukemia

29 October 2022

361

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the East of Scotland and Newcastle Lymphoma Group (ESNLG)

29 October 2022

362

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Histamine release by contrast media

29 October 2022

363

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Inhibition of neurite initiation and growth by taxol

29 October 2022

364

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Branching of sensory and sympathetic neurites in vitro is inhibited by treatment with taxol

29 October 2022

365

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neoplasms of the central nervous system

29 October 2022

366

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

29 October 2022

367

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination immunosuppressive therapy after factor VIII infusion for acquired factor VIII inhibitor

29 October 2022

368

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Slow infusion of vincristine in the treatment of refractory thrombocytopenic purpura

29 October 2022

369

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

CANCER of the kidney and ureter

29 October 2022

370

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The treatment of chronic lymphocytic leukemia with COP chemotherapy

29 October 2022

371

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol produces a predominantly sensory neuropathy

29 October 2022

372

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Salvage therapy in recurrent germ cell cancer: ifosfamide and cisplatin plus either vinblastine or etoposide

29 October 2022

375

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Testicular cancer: the quest continues

29 October 2022

376

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

VAD chemotherapy for refractory multiple myeloma

29 October 2022

377

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of patients with recurrent gliomas with cyclophosphamide and vincristine

29 October 2022

378

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Twenty years of MOPP therapy for Hodgkin's disease

29 October 2022

380

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial

29 October 2022

381

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Histamine release in dogs by Cremophor El® and its derivatives: Oxethylated oleic acid is the most effective constituent

29 October 2022

382

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay

29 October 2022

386

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Randomized comparison of two combination regimens versus minimal chemotherapy in nonsmall-cell lung cancer: a Southeastern Cancer Study Group Trial

29 October 2022

387

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II trial of combination chemotherapy with dacarbazine, cyclophosphamide, cisplatin, doxorubicin, and vindesine (DECAV) in advanced renal cell cancer

29 October 2022

389

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine and mitomycin C in metastatic breast cancer. A Southeastern Cancer Study Group Trial

29 October 2022

390

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Successful chemotherapy for newly diagnosed aggressive oligodendroglioma.

29 October 2022

391

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Interphase action of vinblastine and vincristine: Differences in their lethal action through the mitotic cycle of cultured mammalian cells

29 October 2022

393

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine-induced myocardial infarction

29 October 2022

394

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Preliminary results of alternating combination chemotherapy (CT) and hyperfractionated radiotherapy (HART) in advanced rhabdomyosarcoma (RMS)

29 October 2022

395

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine paracrystals from cultured cells are calcium-stable

29 October 2022

396

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: an antimitotic agent with a new mechanism of action

29 October 2022

397

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol binds to cellular microtubules

29 October 2022

398

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine plus vinblastine in acute childhood leukaemia

29 October 2022

401

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Microtubule arrays in taxol-treated mouse dorsal root ganglion-spinal cord cultures

29 October 2022

402

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Morphological alterations in dorsal root ganglion neurons and supporting cells of organotypic mouse spinal cord-ganglion cultures exposed to taxol

29 October 2022

404

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The current status of the treatment of childhood acute lymphoblastic leukemia

29 October 2022

406

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The Intergroup Rhabdomyosarcoma Study-I. A final report

29 October 2022

407

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Acute vincristine neurotoxicity in the presence of hereditary motor and sensory neuropathy type I.

29 October 2022

409

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

29 October 2022

410

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

29 October 2022

411

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Preparation and biological activity of taxol acetates

29 October 2022

413

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin for locally advanced transitional cell carcinoma of the bladder

29 October 2022

416

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II trial of vindesine in the treatment of lymphomas, breast cancer, and other solid tumors

29 October 2022

417

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil

29 October 2022

419

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Brief Communication: Therapy of Advanced Colorectal Cancer With a Combination of 5-Flourouracil, Methyl-l,3-cis(2-chlorethyl)-1-nitrosourea, and Vincristine2

29 October 2022

421

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

29 October 2022

Multidrug resistance

423

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of bleomycin, dacarbazine (DTIC) and vindesine in disseminated malignant melanoma

29 October 2022

424

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Use of snail neurons in developing quantitative ultrastructural parameters for neurotoxic side effects of Vinca antitumor agents

29 October 2022

425

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Brief Intensive Chemotherapy for Metastatic Non-Small-Cell Lung Cancer: A Phase II Study of the Weekly CODE Regimen

29 October 2022

426

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Interaction of vinblastine with calf brain tubulin: multiple equilibria.

29 October 2022

427

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases

29 October 2022

429

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The comparative clinical pharmacology and pharmacokinetics of vindesine, vincristine, and vinblastine in human patients with cancer

29 October 2022

430

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer

29 October 2022

432

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

29 October 2022

The vinca alkaloids

433

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A comparison of cis-platinum-vindesine and cis-platinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer

29 October 2022

434

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

General toxicity and peripheral nerve alterations induced by chronic vincristine treatment in the rabbit

29 October 2022

435

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine a clinical trial with special reference to neurological side effects

29 October 2022

436

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol, a potent promoter of microtubule assembly, inhibits secretion of plasma proteins in cultured rat hepatocytes

29 October 2022

437

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

29 October 2022

Microtubules

442

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

( 3 H)Vincristine. Preparation and preliminary pharmacology

29 October 2022

445

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The pharmacokinetics of 4-acetyl tritium vinblastine in two patients

29 October 2022

446

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The binding of vincristine, vinblastine and colchicine to tubulin.

29 October 2022

447

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vindesine and vincristine in humans

29 October 2022

449

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients

29 October 2022

450

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Salvage chemotherapy for non Hodgkin's lymphoma of unfavourable histology with a combination of CCNU and vinblastine

29 October 2022

451

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of MOPP-resistant Hodgkin's disease with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD).

29 October 2022

452

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol binds to polymerized tubulin in vitro

29 October 2022

453

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol binds differentially to flagellar outer doublets and their reassembled microtubules

29 October 2022

454

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin

29 October 2022

455

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinblastine, adriamycin, thiotepa, and halotestin (VATH). Therapy for advanced breast cancer refractory to prior chemotherapy

29 October 2022

456

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Nerve Growth Factor Attenuates Neurotoxic Effects of Taxol on Spinal Cord-Ganglion Explants from Fetal Mice

29 October 2022

458

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Preoperative chemotherapy for soft-tissue sarcomas of the extremities

29 October 2022

459

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine infusion with advanced, relapsed tumors.

29 October 2022

460

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Continuous vincristine infusion as part of a high dose chemoradiotherapy regimen: drug kinetics and toxicity

29 October 2022

461

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma. (ENSG 3C induction regimen). The European Neuroblastoma Study Group

29 October 2022

462

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Continuous vindesine infusion in advanced head and neck cancer

29 October 2022

463

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The synthesis of Navelbine prototype of a new series of vinblastine derivatives

29 October 2022

464

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Verapamil reversal of clinical doxorubicin resistance in human cancer. A Wilshire Oncology Medical Group pilot phase I-II study

29 October 2022

465

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparison of three remission induction regimens and two postinduction strategies for the treatment of acute nonlymphocytic leukemia: a cancer and leukemia group B study

29 October 2022

466

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Weekly alternating etoposide, methotrexate, and actinomycin/vincristine and cyclophosphamide chemotherapy for the treatment of CNS metastases of choriocarcinoma

29 October 2022

468

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Clinical pharmacokinetics of vindesine infusion

29 October 2022

471

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Comparative pharmacokinetics of antitumor Vinca alkaloids: intravenous bolus injections of navelbine and related alkaloids to cancer patients and rats

29 October 2022

472

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

In vivo and in vitro pharmacokinetics and metabolism of vincaalkaloids in rat. I. Vindesine (4-deacetyl-vinblastine 3-carboxyamide)

29 October 2022

475

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The effects of taxol, a microtubule-stabilizing drug, on steroidogenic cells

29 October 2022

476

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I and pharmacological study of vinblastine by prolonged continuous infusion

29 October 2022

478

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vindesine as a single agent in the treatment of advanced malignant melanoma

29 October 2022

481

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A phase I-II trial

29 October 2022

482

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Studies With RP 56976 (Taxotere): A Semisynthetic Analogue of Taxol

29 October 2022

484

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Therapeutic response to taxol of six human tumors xenografted into nude mice.

29 October 2022

485

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine-induced changes in the retina of the isolated arterially-perfused cat eye

29 October 2022

488

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Demonstration of the cell cycle positions of taxol-induced "asters" and "bundles" by sequential measurements of tubulin immunofluorescence, DNA content, and autoradiographic labeling of taxol-sensitive and -resistant cells.

29 October 2022

489

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effects of taxol on human neutrophils

29 October 2022

491

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Long-term effectiveness of vincristine in the therapy of refractory autoimmune thrombocytopenia

29 October 2022

493

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer

29 October 2022

494

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine neurotoxicity

29 October 2022

495

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Blast crisis of chronic granulocytic leukemia. Morphologic variants and therapeutic implications

29 October 2022

496

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: a novel investigational antimicrotubule agent

29 October 2022

501

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Sequences of taxol and cisplatin: a phase I and pharmacologic study

29 October 2022

502

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cardiac disturbances during the administration of taxol

29 October 2022

503

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol: Twenty Years Later, the Story Unfolds

29 October 2022

504

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol-induced neuropathy: short-term effects of local injection

29 October 2022

506

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Morphological studies on the effect of taxol on cultured human prostatic cancer cells

29 October 2022

507

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer

29 October 2022

508

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Evaluation of intensification and maintenance programs in the treatment of acute lymphoblastic leukemia

29 October 2022

509

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol stabilization of mitotic spindle microtubules: Analysis using calcium induced depolymerization

29 October 2022

511

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Alternating combination chemotherapy and levamisole improves survival in multiple myeloma: a Southwest Oncology Group Study

29 October 2022

512

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy in germinal cell tumors

29 October 2022

514

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine-induced neuropathy: A clinical study of fifty leukemic patients

29 October 2022

515

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Prolonged disease-free survival in MOPP-resistant Hodgkin's disease after treatment with adriamycin, bleomycin, vinblastine and dacarbazine (ABVD)

29 October 2022

516

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Alternating drug combinations in the treatment of advanced Hodgkin's disease

29 October 2022

517

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Salvage Chemotherapy with ABVD in MOPP-Resistant Hodgkin's Disease

29 October 2022

518

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Acute myelogenous leukaemia: maintenance chemotherapy after early consolidation treatment does not prolong survival

29 October 2022

519

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The administration of radiographic contrast media to patients with a history of a previous reaction

29 October 2022

520

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Non-Hodgkin's lymphoma: Patterns of relapse from complete remission after combination chemotherapy

29 October 2022

521

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma

29 October 2022

522

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion.

29 October 2022

523

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neo-adjuvant chemotherapy for invasive bladder cancer. Experience with the M-VAC regimen

29 October 2022

524

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study

29 October 2022

525

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol stabilizes microtubules in mouse fibroblast cells

29 October 2022

526

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol assembles tubulin in the absence of exogenous guanosine 5'-triphosphate or microtubule-associated proteins

29 October 2022

527

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Promotion of microtubule assembly in vitro by taxol

29 October 2022

528

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of recombinant interferon alpha-2a and vinblastine in advanced renal cell carcinoma.

29 October 2022

529

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

An evaluation of the effect of vincristine added to cyclophosphamide, 5-fluorouracil, methotrexate, and prednisone in advanced breast cancer

29 October 2022

530

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

29 October 2022

532

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics of vincristine sulfate in children

29 October 2022

533

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine and gastrointestinal transit

29 October 2022

538

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Adverse reactions to intravascularly administered contrast media. A comprehensive study based on a prospective survey

29 October 2022

539

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effective chemotherapy consisting of bleomycin, vincristine, mitomycin C, and cisplatin (BOMP) for a patient with inoperable vulvar cancer

29 October 2022

540

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD)

29 October 2022

542

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II trial of vindesine in patients with malignant lymphoma

29 October 2022

543

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro

29 October 2022

544

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Fatal myeloencephalopathy caused by intrathecal vincristine

29 October 2022

545

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Letter: Myocardial infarction: a complication of vincristine treatment?

29 October 2022

548

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Clinicopathological diagnosis and treatment of malignant histiocytosis

29 October 2022

549

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effect of desacetyl vinblastine amide (DVA) against human sarcomas heterotransplanted in nude mice

29 October 2022

551

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vinca alkaloids in the treatment of non-small cell lung cancer

29 October 2022

552

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Therapy of histiocytosis X with vincristine, vinblastine, and cyclophosphamide. The Southwest Cancer Chemotherapy Study Group

29 October 2022

555

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Results of endocrine therapy do not predict response to chemotherapy in advanced breast cancer

29 October 2022

557

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of refractory multiple myeloma with the vincristine-adriamycin-dexamethasone (VAD) regimen

29 October 2022

558

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

29 October 2022

559

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse

29 October 2022

560

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Early-onset thrombocytopenia during combination chemotherapy in testicular cancer is induced by vinblastine

29 October 2022

561

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

High-dose versus low-dose vinblastine in cisplatin-vinblastine-bleomycin combination chemotherapy of non-seminomatous testicular cancer: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group

29 October 2022

562

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Mode of action of chemotherapy in vivo on human acute leukemia—II. Vincristine

29 October 2022

563

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Reappraisal of some dosage adjustment guidelines

29 October 2022

567

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

MVPP chemotherapy regimen for advanced Hodgkin's disease

29 October 2022

568

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Rhizoxin binding to tubulin at the maytansine-binding site.

29 October 2022

570

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase I and pharmacokinetic study of intravenous vinzolidine

29 October 2022

572

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study

29 October 2022

573

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase II study of cisplatin and continuous infusion of vindesine in metastatic head and neck squamous cell cancer

29 October 2022

574

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Raynaud's phenomenon as a side effect of chemotherapy with vinblastine and bleomycin for testicular carcinoma

29 October 2022

575

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Estramustine--a nitrogen mustard/steroid with antimicrotubule activity

29 October 2022

576

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Massive vincristine overdose: failure of leucovorin to reduce toxicity

29 October 2022

579

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Multimodality therapy for medulloblastoma.

29 October 2022

580

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol induces microtubule assembly at low temperature

29 October 2022

581

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effect of taxol on secretory cells: functional, morphological, and electrophysiological correlates

29 October 2022

582

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Two cycles of cisplatin-vindesine and radiotherapy for localized nonsmall cell carcinoma of the lung (stage III). Results of a prospective trial with 149 patients

29 October 2022

583

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Conservative approach to the treatment of chemotherapy-induced extravasation

29 October 2022

586

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Potentiation of chemotherapeutic effect of vincristine in vincristine resistant tumor bearing mice by calmodulin inhibitor clomipramine

29 October 2022

588

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Effects of quinidine and related compounds on cytotoxicity and cellular accumulation of vincristine and adriamycin in drug-resistant tumor cells

29 October 2022

589

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Modification of cytotoxic drug resistance by non-immuno-suppressive cyclosporins

29 October 2022

591

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I and II studies of vindesine

29 October 2022

592

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination

29 October 2022

594

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Combination of cisplatin, vindesine, and dacarbazine in advanced malignant melanoma. A Phase II Study of the EORTC Malignant Melanoma Cooperative Group

29 October 2022

595

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study

29 October 2022

596

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A phase II trial of continuous infusion vinblastine in patients with gastric carcinoma. A Southwest Oncology Group study

29 October 2022

599

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The acute effects of taxol upon regenerating axons after nerve crush

29 October 2022

600

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

The acute response of Schwann cells to taxol after nerve crush

29 October 2022

601

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Factors affecting remission and survival in patients with advanced Hodgkin's disease treated with MVPP

29 October 2022

603

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Changes in the hydrodynamic properties of microtubules induced by taxol.

29 October 2022

605

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia

29 October 2022

606

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Some biological effects of Vincaleukoblastine, an alkaloid in Vinca rosea Linn in patients with malignant disease

29 October 2022

608

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Vincristine infusion. A phase I study

29 October 2022

609

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Unusual cardiac reaction to chemotherapy following mediastinal irradiation in a patient with Hodgkin's disease

29 October 2022

612

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Neurotoxicity of commonly used antineoplastic agents (second of two parts).

29 October 2022

613

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Hypersensitivity reactions from taxol

29 October 2022

614

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Rapid improvement of thrombotic thrombocytopenic purpura with vincristine and plasmapheresis

29 October 2022

615

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Bleomycin, vincristine, and mitomycin C (BOM) as second-line treatment after failure of cis-platinum-based combination chemotherapy for recurrent cervical cancer

29 October 2022

617

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

29 October 2022

618

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Resistance and cross-resistance of cultured leukemia P388 cells to vincristine, adriamycin, adriamycin analogs, and actinomycin D

29 October 2022

620

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Ascending myeloencephalopathy due to intrathecal vincristine sulfate. A fatal chemotherapeutic error

29 October 2022

622

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide

29 October 2022

623

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group

29 October 2022

624

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Mechanism of action of vinblastine. Binding of [acetyl-3H]-vinblastine to embryonic chick brain tubulin and tubulin from sea urchin sperm tail outer doublet microtubules

29 October 2022

625

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Taxol stabilization of microtubules in vitro: dynamics of tubulin addition and loss at opposite microtubule ends.

29 October 2022

626

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of germ cell tumors of the testis. I. Induction of remissions with vinblastine, actinomycin D, and bleomycin

29 October 2022

629

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Phase II study of vindesine sulfate in the therapy for advanced renal carcinoma

29 October 2022

631

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer

29 October 2022

632

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Chemotherapy of urothelial tract tumors

29 October 2022

634

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A randomized study of continuous infusion vindesine versus vinblastine in adults with refractory metastatic sarcomas

29 October 2022

636

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma

29 October 2022

639

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Bleomycin, vincristine, lomustine, and DTIC chemotherapy for metastatic melanoma

29 October 2022

640

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine

29 October 2022

641

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

Partially reversible nerve deafness due to vincristine

29 October 2022

643

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

cis-platinum/vinblastine/bleomycin combination chemotherapy in advanced or recurrent granulosa cell tumors of the ovary

29 October 2022

644

1 reference

https://api.crossref.org/works/10.1016/0163-7258(91)90086-2

29 October 2022

Identifiers

1 reference

3 August 2017

1 reference